U.S. Trade Commission Imposes Seven-Year Ban on Ascletis Liver Drugs Imports
The U.S. International Trade Commission (ITC) has taken a definitive stance against a Hong Kong-listed pharmaceutical company, Ascletis, by issuing an order that bars the import of its liver disease treatments into the United States for a period of seven years. This decision marks a significant development in the regulatory landscape affecting pharmaceutical imports and…